Snapshot from Aug 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Median Technologies Olea Medical...
Business commercial agreement

Median Technologies Olea Medical eyonis LCS partnership

Analysis based on 8 articles · First reported Jul 30, 2026 · Last updated Aug 03, 2026

Sentiment
30
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The partnership is expected to accelerate adoption of eyonis LCS, potentially increasing revenue for Median Technologies and strengthening its position in the AI medical imaging market. For Ventana Medical Systems and Olea Medical, it expands their AI-enabled product portfolio and reinforces their presence in lung cancer screening.

Medical Imaging Healthcare Technology Artificial Intelligence in Healthcare
Event Summary

Median Technologies, through its subsidiary Eyonis Inc., has entered into a strategic commercial agreement with Olea Medical, a Ventana Medical Systems company, to expand U.S. and European access to eyonis LCS, an FDA-cleared AI-powered Software as a Medical Device for lung cancer screening. The agreement leverages Olea Medical's relationships with radiology providers and healthcare systems to commercialize eyonis LCS, which detects pulmonary nodules and assesses malignancy likelihood on low-dose CT. Clinical study data showed improved sensitivity and specificity for radiologists using the technology. This partnership follows a previous agreement with Tempus AI and is part of Median Technologies' strategy to scale adoption of eyonis LCS. The product received FDA clearance in February 2026 and CE marking in July 2026.

Key Actions
90 Median Technologies signed commercial agreement Olea Medical
80 Olea Medical will support commercialization Median Technologies
Entities Involved
stock
Median Technologies
Median Technologies is the primary beneficiary, gaining a strategic distribution channel through Olea Medical to expand market reach for its eyonis LCS product, potentially boosting sales and market share.
Importance 100.0 Sentiment 70.0
priv
Olea Medical
Olea Medical will commercialize eyonis LCS, leveraging its radiology network, which could enhance its product portfolio and revenue streams.
Importance 90.0 Sentiment 60.0
priv
Eyonis Inc.
Eyonis Inc., the developer of eyonis LCS, benefits from expanded commercialization efforts, potentially increasing product adoption and revenue.
Importance 80.0 Sentiment 65.0
priv
Ventana Medical Systems
As parent of Olea Medical, Ventana Medical Systems gains access to an AI-powered lung cancer screening solution, strengthening its CT imaging ecosystem and competitive position.
Importance 70.0 Sentiment 55.0
cnt
United States
The U.S. is a primary market for eyonis LCS, with FDA clearance enabling commercial deployment; the agreement expands access to U.S. radiology providers.
Importance 60.0 Sentiment 50.0
per
Fredrik Brag
As CEO and Founder of Median Technologies, Fredrik Brag is a key executive driving the partnership strategy.
Importance 50.0 Sentiment 55.0
loc
Europe
Europe is another key market, with CE marking allowing commercialization; the agreement covers European markets.
Importance 50.0 Sentiment 50.0
govactor
United States — Food and Drug Administration
The FDA cleared eyonis LCS, enabling its U.S. commercialization; this regulatory approval is foundational to the agreement.
Importance 50.0 Sentiment 50.0
per
Oran Muduroglu
As President of Eyonis, Oran Muduroglu is a spokesperson for the agreement, representing the company's commercial interests.
Importance 40.0 Sentiment 50.0
per
Fayçal Djeridane
As President of Olea Medical, Fayçal Djeridane is a key executive in the partnership, representing Olea Medical's interests.
Importance 40.0 Sentiment 50.0
cnt
France
France is the headquarters of Median Technologies and Olea Medical, but the agreement's impact on France is indirect.
Importance 30.0 Sentiment 45.0
priv
Tempus AI
Tempus AI is mentioned as a prior partner, indicating an existing relationship with Median Technologies, but is not directly involved in this agreement.
Importance 30.0 Sentiment 40.0
cnt
China
China is mentioned as a location of operations for Median Technologies, but not directly involved in this agreement.
Importance 20.0 Sentiment 40.0
exch
Euronext Paris
Median Technologies is listed on Euronext Paris; the agreement may positively influence its stock performance.
Importance 20.0 Sentiment 45.0
Relationships
Ventana Medical Systems related ↔ United States
United States related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.